JP2013518908A5

JP2013518908A5 -

Download PDF

Info

Publication number: JP2013518908A5
Authority: JP; Japan
Prior art keywords: derivative; glucocorticoid; refractory; metabolite; disease
Prior art date: 2011-02-07
Legal status : Granted

Application number

JP2012552135A

Other languages

English (en)

Japanese (ja)

Other versions

JP5913136B2 (ja

JP2013518908A (ja

Filing date

2011-02-07

Publication date

2014-03-20

2011-02-07 Application filed filed Critical

2011-02-07 Priority claimed from PCT/US2011/023917 external-priority patent/WO2011097571A2/en

2013-05-23 Publication of JP2013518908A publication Critical patent/JP2013518908A/ja

2014-03-20 Publication of JP2013518908A5 publication Critical patent/JP2013518908A5/ja

2016-04-27 Application granted granted Critical

2016-04-27 Publication of JP5913136B2 publication Critical patent/JP5913136B2/ja

Status Active legal-status Critical Current

2031-02-07 Anticipated expiration legal-status Critical

Links

239000003246 corticosteroid Substances 0.000 claims description 138
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 125
239000003862 glucocorticoid Substances 0.000 claims description 122
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims description 86
229950000801 hydroxyprogesterone caproate Drugs 0.000 claims description 82
150000003431 steroids Chemical class 0.000 claims description 77
229960003387 progesterone Drugs 0.000 claims description 62
239000000186 progesterone Substances 0.000 claims description 62
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 61
208000024891 symptom Diseases 0.000 claims description 59
238000011282 treatment Methods 0.000 claims description 52
201000010099 disease Diseases 0.000 claims description 47
239000000583 progesterone congener Substances 0.000 claims description 45
230000035945 sensitivity Effects 0.000 claims description 45
239000002207 metabolite Substances 0.000 claims description 39
238000000034 method Methods 0.000 claims description 39
230000001419 dependent effect Effects 0.000 claims description 36
229960001334 corticosteroids Drugs 0.000 claims description 35
-1 amine salts Chemical class 0.000 claims description 32
208000006673 asthma Diseases 0.000 claims description 29
239000003270 steroid hormone Substances 0.000 claims description 28
230000005764 inhibitory process Effects 0.000 claims description 26
239000008194 pharmaceutical composition Substances 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 22
230000027758 ovulation cycle Effects 0.000 claims description 22
230000006866 deterioration Effects 0.000 claims description 16
230000004043 responsiveness Effects 0.000 claims description 16
206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
229940037128 systemic glucocorticoids Drugs 0.000 claims description 14
208000027866 inflammatory disease Diseases 0.000 claims description 13
230000002757 inflammatory effect Effects 0.000 claims description 13
230000002441 reversible effect Effects 0.000 claims description 13
208000035475 disorder Diseases 0.000 claims description 12
230000001965 increasing effect Effects 0.000 claims description 12
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 11
102000004127 Cytokines Human genes 0.000 claims description 11
108090000695 Cytokines Proteins 0.000 claims description 11
229960004400 levonorgestrel Drugs 0.000 claims description 11
208000015181 infectious disease Diseases 0.000 claims description 10
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 9
201000011152 Pemphigus Diseases 0.000 claims description 9
239000003470 adrenal cortex hormone Substances 0.000 claims description 9
RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims description 9
238000009472 formulation Methods 0.000 claims description 9
229960000485 methotrexate Drugs 0.000 claims description 9
201000006417 multiple sclerosis Diseases 0.000 claims description 9
201000001976 pemphigus vulgaris Diseases 0.000 claims description 9
208000011580 syndromic disease Diseases 0.000 claims description 9
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 8
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
208000005987 polymyositis Diseases 0.000 claims description 8
208000011231 Crohn disease Diseases 0.000 claims description 7
201000004624 Dermatitis Diseases 0.000 claims description 7
206010012438 Dermatitis atopic Diseases 0.000 claims description 7
208000029523 Interstitial Lung disease Diseases 0.000 claims description 7
ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 claims description 7
201000008937 atopic dermatitis Diseases 0.000 claims description 7
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 7
229960004976 desogestrel Drugs 0.000 claims description 7
229960003309 dienogest Drugs 0.000 claims description 7
AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 7
GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims description 7
229960001858 norethynodrel Drugs 0.000 claims description 7
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
208000007465 Giant cell arteritis Diseases 0.000 claims description 6
206010025323 Lymphomas Diseases 0.000 claims description 6
238000001990 intravenous administration Methods 0.000 claims description 6
229940053934 norethindrone Drugs 0.000 claims description 6
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 6
206010043207 temporal arteritis Diseases 0.000 claims description 6
230000000699 topical effect Effects 0.000 claims description 6
206010012735 Diarrhoea Diseases 0.000 claims description 5
208000000112 Myalgia Diseases 0.000 claims description 5
208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
230000004054 inflammatory process Effects 0.000 claims description 5
206010025135 lupus erythematosus Diseases 0.000 claims description 5
206010028417 myasthenia gravis Diseases 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
201000000306 sarcoidosis Diseases 0.000 claims description 5
ISHXLNHNDMZNMC-VTKCIJPMSA-N (3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C\1 ISHXLNHNDMZNMC-VTKCIJPMSA-N 0.000 claims description 4
NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 claims description 4
208000023275 Autoimmune disease Diseases 0.000 claims description 4
208000018137 Extraocular muscle disease Diseases 0.000 claims description 4
208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
206010061218 Inflammation Diseases 0.000 claims description 4
208000011200 Kawasaki disease Diseases 0.000 claims description 4
YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 claims description 4
206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
206010029164 Nephrotic syndrome Diseases 0.000 claims description 4
208000004931 Orbital Myositis Diseases 0.000 claims description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
241001303601 Rosacea Species 0.000 claims description 4
201000010848 Schnitzler Syndrome Diseases 0.000 claims description 4
208000004732 Systemic Vasculitis Diseases 0.000 claims description 4
206010047115 Vasculitis Diseases 0.000 claims description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
230000033228 biological regulation Effects 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
229960003843 cyproterone Drugs 0.000 claims description 4
229960001853 demegestone Drugs 0.000 claims description 4
JWAHBTQSSMYISL-MHTWAQMVSA-N demegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 JWAHBTQSSMYISL-MHTWAQMVSA-N 0.000 claims description 4
201000001981 dermatomyositis Diseases 0.000 claims description 4
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 4
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
229960002941 etonogestrel Drugs 0.000 claims description 4
230000009610 hypersensitivity Effects 0.000 claims description 4
238000002347 injection Methods 0.000 claims description 4
239000007924 injection Substances 0.000 claims description 4
229960001910 lynestrenol Drugs 0.000 claims description 4
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 4
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 4
206010065579 multifocal motor neuropathy Diseases 0.000 claims description 4
230000001114 myogenic effect Effects 0.000 claims description 4
229960002667 norelgestromin Drugs 0.000 claims description 4
229960000417 norgestimate Drugs 0.000 claims description 4
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 4
201000010668 orbital plasma cell granuloma Diseases 0.000 claims description 4
229960001584 promegestone Drugs 0.000 claims description 4
QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 claims description 4
230000000306 recurrent effect Effects 0.000 claims description 4
201000004700 rosacea Diseases 0.000 claims description 4
230000000391 smoking effect Effects 0.000 claims description 4
JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 claims description 4
229950008546 trimegestone Drugs 0.000 claims description 4
206010001367 Adrenal insufficiency Diseases 0.000 claims description 3
208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 3
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
201000003883 Cystic fibrosis Diseases 0.000 claims description 3
208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
241000721454 Pemphigus Species 0.000 claims description 3
206010040047 Sepsis Diseases 0.000 claims description 3
206010053879 Sepsis syndrome Diseases 0.000 claims description 3
206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 3
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 3
206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
206010046851 Uveitis Diseases 0.000 claims description 3
208000017515 adrenocortical insufficiency Diseases 0.000 claims description 3
201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 3
229960000218 etynodiol Drugs 0.000 claims description 3
208000024908 graft versus host disease Diseases 0.000 claims description 3
238000010255 intramuscular injection Methods 0.000 claims description 3
239000007927 intramuscular injection Substances 0.000 claims description 3
229960004616 medroxyprogesterone Drugs 0.000 claims description 3
230000009854 mucosal lesion Effects 0.000 claims description 3
229960004719 nandrolone Drugs 0.000 claims description 3
NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims description 3
210000000056 organ Anatomy 0.000 claims description 3
230000002685 pulmonary effect Effects 0.000 claims description 3
230000009885 systemic effect Effects 0.000 claims description 3
229960001023 tibolone Drugs 0.000 claims description 3
WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 claims description 3
230000001256 tonic effect Effects 0.000 claims description 3
238000002054 transplantation Methods 0.000 claims description 3
208000026872 Addison Disease Diseases 0.000 claims description 2
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
208000019901 Anxiety disease Diseases 0.000 claims description 2
206010048962 Brain oedema Diseases 0.000 claims description 2
206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims description 2
206010006811 Bursitis Diseases 0.000 claims description 2
208000014311 Cushing syndrome Diseases 0.000 claims description 2
208000034423 Delivery Diseases 0.000 claims description 2
206010012442 Dermatitis contact Diseases 0.000 claims description 2
206010012455 Dermatitis exfoliative Diseases 0.000 claims description 2
206010013700 Drug hypersensitivity Diseases 0.000 claims description 2
206010016654 Fibrosis Diseases 0.000 claims description 2
208000010412 Glaucoma Diseases 0.000 claims description 2
206010018691 Granuloma Diseases 0.000 claims description 2
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
206010019860 Hereditary angioedema Diseases 0.000 claims description 2
206010021143 Hypoxia Diseases 0.000 claims description 2
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
206010027259 Meningitis tuberculous Diseases 0.000 claims description 2
208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
208000019022 Mood disease Diseases 0.000 claims description 2
208000000592 Nasal Polyps Diseases 0.000 claims description 2
206010065673 Nephritic syndrome Diseases 0.000 claims description 2
208000008589 Obesity Diseases 0.000 claims description 2
206010067472 Organising pneumonia Diseases 0.000 claims description 2
206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
208000005384 Pneumocystis Pneumonia Diseases 0.000 claims description 2
206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims description 2
206010065159 Polychondritis Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
208000025747 Rheumatic disease Diseases 0.000 claims description 2
206010039085 Rhinitis allergic Diseases 0.000 claims description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
206010067130 Spastic diplegia Diseases 0.000 claims description 2
208000000491 Tendinopathy Diseases 0.000 claims description 2
206010043255 Tendonitis Diseases 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
206010044608 Trichiniasis Diseases 0.000 claims description 2
208000022971 Tuberculous meningitis Diseases 0.000 claims description 2
208000024780 Urticaria Diseases 0.000 claims description 2
208000036142 Viral infection Diseases 0.000 claims description 2
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
201000005255 adrenal gland hyperfunction Diseases 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims description 2
201000010105 allergic rhinitis Diseases 0.000 claims description 2
230000036506 anxiety Effects 0.000 claims description 2
230000006907 apoptotic process Effects 0.000 claims description 2
230000001363 autoimmune Effects 0.000 claims description 2
239000002585 base Substances 0.000 claims description 2
230000003115 biocidal effect Effects 0.000 claims description 2
208000006752 brain edema Diseases 0.000 claims description 2
206010008129 cerebral palsy Diseases 0.000 claims description 2
238000002512 chemotherapy Methods 0.000 claims description 2
229960003996 chlormadinone Drugs 0.000 claims description 2
208000020832 chronic kidney disease Diseases 0.000 claims description 2
208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
230000007882 cirrhosis Effects 0.000 claims description 2
208000019425 cirrhosis of liver Diseases 0.000 claims description 2
208000010247 contact dermatitis Diseases 0.000 claims description 2
201000009805 cryptogenic organizing pneumonia Diseases 0.000 claims description 2
230000001186 cumulative effect Effects 0.000 claims description 2
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 2
229960004845 drospirenone Drugs 0.000 claims description 2
150000002084 enol ethers Chemical class 0.000 claims description 2
230000012010 growth Effects 0.000 claims description 2
230000003463 hyperproliferative effect Effects 0.000 claims description 2
208000018875 hypoxemia Diseases 0.000 claims description 2
208000018022 idiopathic eosinophilic pneumonia Diseases 0.000 claims description 2
206010022437 insomnia Diseases 0.000 claims description 2
208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
238000001361 intraarterial administration Methods 0.000 claims description 2
238000007912 intraperitoneal administration Methods 0.000 claims description 2
230000013016 learning Effects 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims description 2
229960001786 megestrol Drugs 0.000 claims description 2
208000001223 meningeal tuberculosis Diseases 0.000 claims description 2
229910052751 metal Chemical class 0.000 claims description 2
239000002184 metal Chemical class 0.000 claims description 2
201000005962 mycosis fungoides Diseases 0.000 claims description 2
201000000050 myeloid neoplasm Diseases 0.000 claims description 2
235000020824 obesity Nutrition 0.000 claims description 2
230000000414 obstructive effect Effects 0.000 claims description 2
201000008482 osteoarthritis Diseases 0.000 claims description 2
201000000317 pneumocystosis Diseases 0.000 claims description 2
201000009395 primary hyperaldosteronism Diseases 0.000 claims description 2
239000000651 prodrug Substances 0.000 claims description 2
229940002612 prodrug Drugs 0.000 claims description 2
201000001474 proteinuria Diseases 0.000 claims description 2
208000008128 pulmonary tuberculosis Diseases 0.000 claims description 2
208000009169 relapsing polychondritis Diseases 0.000 claims description 2
230000000552 rheumatic effect Effects 0.000 claims description 2
201000003068 rheumatic fever Diseases 0.000 claims description 2
201000000980 schizophrenia Diseases 0.000 claims description 2
206010040400 serum sickness Diseases 0.000 claims description 2
239000012453 solvate Substances 0.000 claims description 2
208000020431 spinal cord injury Diseases 0.000 claims description 2
238000007920 subcutaneous administration Methods 0.000 claims description 2
201000006489 suppurative thyroiditis Diseases 0.000 claims description 2
201000004415 tendinitis Diseases 0.000 claims description 2
206010043554 thrombocytopenia Diseases 0.000 claims description 2
229910052723 transition metal Inorganic materials 0.000 claims description 2
208000003982 trichinellosis Diseases 0.000 claims description 2
201000007588 trichinosis Diseases 0.000 claims description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
230000009677 vaginal delivery Effects 0.000 claims description 2
230000009385 viral infection Effects 0.000 claims description 2
DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims 2
DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 claims 2
208000035143 Bacterial infection Diseases 0.000 claims 1
206010008909 Chronic Hepatitis Diseases 0.000 claims 1
206010012441 Dermatitis bullous Diseases 0.000 claims 1
206010018910 Haemolysis Diseases 0.000 claims 1
206010019755 Hepatitis chronic active Diseases 0.000 claims 1
201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
208000030852 Parasitic disease Diseases 0.000 claims 1
241000606651 Rickettsiales Species 0.000 claims 1
VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 claims 1
150000007513 acids Chemical class 0.000 claims 1
230000001154 acute effect Effects 0.000 claims 1
230000001919 adrenal effect Effects 0.000 claims 1
208000007502 anemia Diseases 0.000 claims 1
208000022362 bacterial infectious disease Diseases 0.000 claims 1
210000003123 bronchiole Anatomy 0.000 claims 1
VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 claims 1
239000002934 diuretic Substances 0.000 claims 1
230000001882 diuretic effect Effects 0.000 claims 1
230000004064 dysfunction Effects 0.000 claims 1
ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims 1
230000008588 hemolysis Effects 0.000 claims 1
150000004677 hydrates Chemical class 0.000 claims 1
210000003016 hypothalamus Anatomy 0.000 claims 1
FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 claims 1
210000004165 myocardium Anatomy 0.000 claims 1
208000016366 nasal cavity polyp Diseases 0.000 claims 1
210000005036 nerve Anatomy 0.000 claims 1
229960004911 nomegestrol Drugs 0.000 claims 1
KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 claims 1
206010039083 rhinitis Diseases 0.000 claims 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 79
229960003957 dexamethasone Drugs 0.000 description 78
108010002350 Interleukin-2 Proteins 0.000 description 66
230000000694 effects Effects 0.000 description 58
230000004044 response Effects 0.000 description 41
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 40
108010047620 Phytohemagglutinins Proteins 0.000 description 39
230000001885 phytohemagglutinin Effects 0.000 description 39
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 30
229960002985 medroxyprogesterone acetate Drugs 0.000 description 27
239000003814 drug Substances 0.000 description 25
210000004027 cell Anatomy 0.000 description 23
229940079593 drug Drugs 0.000 description 23
102000003676 Glucocorticoid Receptors Human genes 0.000 description 19
108090000079 Glucocorticoid Receptors Proteins 0.000 description 19
102000043136 MAP kinase family Human genes 0.000 description 17
108091054455 MAP kinase family Proteins 0.000 description 17
230000003110 anti-inflammatory effect Effects 0.000 description 16
230000001629 suppression Effects 0.000 description 16
102000004388 Interleukin-4 Human genes 0.000 description 15
108090000978 Interleukin-4 Proteins 0.000 description 15
230000014509 gene expression Effects 0.000 description 14
238000002965 ELISA Methods 0.000 description 12
230000002411 adverse Effects 0.000 description 12
230000006872 improvement Effects 0.000 description 12
108700011498 Glucocorticoid Receptor Deficiency Proteins 0.000 description 11
150000001875 compounds Chemical class 0.000 description 11
208000026352 glucocorticoid resistance Diseases 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
230000000638 stimulation Effects 0.000 description 10
206010065687 Bone loss Diseases 0.000 description 8
206010020751 Hypersensitivity Diseases 0.000 description 8
208000001388 Opportunistic Infections Diseases 0.000 description 8
230000004913 activation Effects 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
230000009467 reduction Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
238000012384 transportation and delivery Methods 0.000 description 8
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
208000026935 allergic disease Diseases 0.000 description 7
229910002091 carbon monoxide Inorganic materials 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 7
230000036737 immune function Effects 0.000 description 7
239000002085 irritant Substances 0.000 description 7
231100000021 irritant Toxicity 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
230000007815 allergy Effects 0.000 description 6
239000000427 antigen Substances 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
230000001976 improved effect Effects 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 6
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 6
239000000725 suspension Substances 0.000 description 6
102000011423 Histone Deacetylase 2 Human genes 0.000 description 5
108010023981 Histone Deacetylase 2 Proteins 0.000 description 5
230000009471 action Effects 0.000 description 5
229960000978 cyproterone acetate Drugs 0.000 description 5
230000004073 interleukin-2 production Effects 0.000 description 5
230000016087 ovulation Effects 0.000 description 5
230000035935 pregnancy Effects 0.000 description 5
238000013207 serial dilution Methods 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 4
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
108010036949 Cyclosporine Proteins 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229940022663 acetate Drugs 0.000 description 4
229940046731 calcineurin inhibitors Drugs 0.000 description 4
210000003855 cell nucleus Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
229960001265 ciclosporin Drugs 0.000 description 4
229930182912 cyclosporin Natural products 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
239000003163 gonadal steroid hormone Substances 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000002175 menstrual effect Effects 0.000 description 4
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 4
230000009456 molecular mechanism Effects 0.000 description 4
239000013642 negative control Substances 0.000 description 4
229960004190 nomegestrol acetate Drugs 0.000 description 4
IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
230000002265 prevention Effects 0.000 description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000002177 Cataract Diseases 0.000 description 3
VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
206010034156 Pathological fracture Diseases 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
208000005250 Spontaneous Fractures Diseases 0.000 description 3
229940124630 bronchodilator Drugs 0.000 description 3
229960005309 estradiol Drugs 0.000 description 3
JYILPERKVHXLNF-QMNUTNMBSA-N ethynodiol Chemical compound O[C@H]1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 JYILPERKVHXLNF-QMNUTNMBSA-N 0.000 description 3
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000007726 management method Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002483 medication Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000036542 oxidative stress Effects 0.000 description 3
229960005205 prednisolone Drugs 0.000 description 3
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
238000011160 research Methods 0.000 description 3
210000001599 sigmoid colon Anatomy 0.000 description 3
239000002904 solvent Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 2
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000003893 Histone acetyltransferases Human genes 0.000 description 2
108090000246 Histone acetyltransferases Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
239000012825 JNK inhibitor Substances 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
229940122696 MAP kinase inhibitor Drugs 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 2
229940049937 Pgp inhibitor Drugs 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
208000005107 Premature Birth Diseases 0.000 description 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108091027981 Response element Proteins 0.000 description 2
229940124639 Selective inhibitor Drugs 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
229930003316 Vitamin D Natural products 0.000 description 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
239000012190 activator Substances 0.000 description 2
208000010981 acute adrenal insufficiency Diseases 0.000 description 2
238000011374 additional therapy Methods 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
229950000210 beclometasone dipropionate Drugs 0.000 description 2
229940092705 beclomethasone Drugs 0.000 description 2
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
229960002537 betamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
229960004436 budesonide Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229960001616 chlormadinone acetate Drugs 0.000 description 2
229960003290 cortisone acetate Drugs 0.000 description 2
229960004486 desoxycorticosterone acetate Drugs 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
229960004913 dydrogesterone Drugs 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
230000029142 excretion Effects 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 2
229960000676 flunisolide Drugs 0.000 description 2
229960003336 fluorocortisol acetate Drugs 0.000 description 2
229960000618 fluprednisolone Drugs 0.000 description 2
229960002714 fluticasone Drugs 0.000 description 2
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 2
229960000289 fluticasone propionate Drugs 0.000 description 2
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
239000002748 glycoprotein P inhibitor Substances 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
229940076085 gold Drugs 0.000 description 2
230000036541 health Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000028993 immune response Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000000495 immunoinflammatory effect Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000029849 luteinization Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229960000606 medrogestone Drugs 0.000 description 2
HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 2
229960004296 megestrol acetate Drugs 0.000 description 2
229960001428 mercaptopurine Drugs 0.000 description 2
229960004584 methylprednisolone Drugs 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229960001652 norethindrone acetate Drugs 0.000 description 2
238000007427 paired t-test Methods 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000000843 powder Substances 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
150000003145 progesterone derivatives Chemical class 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
208000034207 response to glucocorticoid therapy Diseases 0.000 description 2
230000000630 rising effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
229960001967 tacrolimus Drugs 0.000 description 2
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
229960000278 theophylline Drugs 0.000 description 2
230000004797 therapeutic response Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000005945 translocation Effects 0.000 description 2
229960005294 triamcinolone Drugs 0.000 description 2
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
229960002117 triamcinolone acetonide Drugs 0.000 description 2
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
235000019166 vitamin D Nutrition 0.000 description 2
239000011710 vitamin D Substances 0.000 description 2
150000003710 vitamin D derivatives Chemical class 0.000 description 2
229940046008 vitamin d Drugs 0.000 description 2
XMRPGKVKISIQBV-UHFFFAOYSA-N (+-)-5- Pregnane-3,20-dione Natural products C1CC2CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 XMRPGKVKISIQBV-UHFFFAOYSA-N 0.000 description 1
RJKFOVLPORLFTN-HQZYFCCVSA-N (8s,9r,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-HQZYFCCVSA-N 0.000 description 1
150000000318 19-norprogesterones Chemical class 0.000 description 1
150000000319 19-nortestosterones Chemical class 0.000 description 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 description 1
XMRPGKVKISIQBV-BJMCWZGWSA-N 5alpha-pregnane-3,20-dione Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 XMRPGKVKISIQBV-BJMCWZGWSA-N 0.000 description 1
JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008169 Co-Repressor Proteins Human genes 0.000 description 1
108010060434 Co-Repressor Proteins Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010008165 Etanercept Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000001204 Hashimoto Disease Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
229940118135 JNK inhibitor Drugs 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
108010057466 NF-kappa B Proteins 0.000 description 1
102000003945 NF-kappa B Human genes 0.000 description 1
108010014632 NF-kappa B kinase Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
241000287463 Phalacrocorax Species 0.000 description 1
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
108010058864 Phospholipases A2 Proteins 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
102100030416 Stromelysin-1 Human genes 0.000 description 1
101710108790 Stromelysin-1 Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000037114 Symptom Flare Up Diseases 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102100023132 Transcription factor Jun Human genes 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000032683 aging Effects 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229960000510 ammonia Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
238000009246 art therapy Methods 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
206010071572 autoimmune progesterone dermatitis Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
208000010928 autoimmune thyroid disease Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
210000001754 blood buffy coat Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
208000017760 chronic graft versus host disease Diseases 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
230000003081 coactivator Effects 0.000 description 1
238000000576 coating method Methods 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960000403 etanercept Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000003325 follicular Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
UACIBCPNAKBWHX-CTBOZYAPSA-N gonane Chemical compound C1CCC[C@@H]2[C@H]3CC[C@@H]4CCC[C@H]4[C@@H]3CCC21 UACIBCPNAKBWHX-CTBOZYAPSA-N 0.000 description 1
210000002503 granulosa cell Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
230000006197 histone deacetylation Effects 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
108091006086 inhibitor proteins Proteins 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000000938 luteal effect Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
UPKIHOQVIBBESY-UHFFFAOYSA-N magnesium;carbanide Chemical compound [CH3-].[CH3-].[Mg+2] UPKIHOQVIBBESY-UHFFFAOYSA-N 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
230000004630 mental health Effects 0.000 description 1
229960005108 mepolizumab Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000007510 mood change Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000019079 negative regulation of cytokine secretion Effects 0.000 description 1
230000006213 negative regulation of lymphocyte proliferation Effects 0.000 description 1
230000008689 nuclear function Effects 0.000 description 1
230000005937 nuclear translocation Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000008789 oxidative DNA damage Effects 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
230000005004 positive regulation of lymphocyte proliferation Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000757 progestagenic effect Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
210000003289 regulatory T cell Anatomy 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
208000017443 reproductive system disease Diseases 0.000 description 1
230000019254 respiratory burst Effects 0.000 description 1
230000024977 response to activity Effects 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000013125 spirometry Methods 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical class C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
108091006108 transcriptional coactivators Proteins 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

JP2012552135A 2010-02-08 2011-02-07 糖質コルチコイド感作物質としてのプロゲストーゲンの使用方法 Active JP5913136B2 (ja)